0.31 +0.00 (0.00%)
GNBT
| Trade GNBT now with |
Stock Details
Last Trade:0.31 Change:+0.00 (0.00%) Prev Close:0.31 Open: 0.17 Days Range:0.31 – 0.31 52 Week Range: 0.08 - 0.33 Volume:1066504 P/E: N/AEPS:-0.08
Recent Blog Posts
Blog Posts on 06/02/11 at 5:07am
Filling an Unmet Need: A Look at Generex and RXI Pharma's Breast Cancer Vaccines
Filling an Unmet Need: A Look at Generex and RXI Pharma's Breast Cancer Vaccines
Blog Posts on 05/06/11 at 10:55am
Mannkind/Generex: Both on the Brink of Diabetic Insulin Spray Breakthrough
Mannkind/Generex: Both on the Brink of Diabetic Insulin Spray Breakthrough
Blog Posts on 12/10/10 at 3:33am
Generex Taps Former Eli Lilly Medical Director to Strengthen Clinical and Regulatory Efforts
Generex Taps Former Eli Lilly Medical Director to Strengthen Clinical and Regulatory Efforts
Blog Posts on 10/28/10 at 10:48am
Talking Big Pharma, Vaccines and Baseball With Generex's Dr. Eric von Hofe
Talking Big Pharma, Vaccines and Baseball With Generex's Dr. Eric von Hofe
Blog Posts on 10/12/10 at 4:45am
Generex 's Acquisition Into the Direct to Consumer Diabetes Market Provides Synergistic Value
Generex 's Acquisition Into the Direct to Consumer Diabetes Market Provides Synergistic Value
Blog Posts on 08/16/10 at 8:35am
Good News for Generex: Positive Data on Oral Insulin Coming in September
Good News for Generex: Positive Data on Oral Insulin Coming in September
Blog Posts on 04/29/10 at 11:07am
Generex's Insulin Product: When a Company Misrepresents 'Compassionate Use'
Generex's Insulin Product: When a Company Misrepresents 'Compassionate Use'
Blog Posts on 04/14/10 at 4:34am
Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy
Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy
Blog Posts on 04/11/10 at 8:30am
Tengion's IPO Comes In Well Below Initial Range: Biotech's Latest Deals, Financings
Tengion's IPO Comes In Well Below Initial Range: Biotech's Latest Deals, Financings
Blog Posts on 04/11/10 at 7:01am
FDA Concerned About Forest Labs Drug: Biotech's Latest Missed Targets, Mishaps
FDA Concerned About Forest Labs Drug: Biotech's Latest Missed Targets, Mishaps


